SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.

Trial Details

NCT ID
NCT06394492
Phase
PHASE3
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • SHR-A1921
  • Doxorubicin
  • Paclitaxel
  • Topotecan
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Voluntary participation and written informed consent.
  • 18 years and older, female.
  • Pathologically diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
  • Patients must have platinum-resistant disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →